ProBio is now licensing the CHOK1 cell line development system to biopharma companies for commercial use

CHOK1-GenS&CHOK1-ADCC+

Cell Line Development System Commercial License

ProBio has 12 years of experience in mammalian cell line development [https://www.probiocdmo.com/add-host-cell-license.html], and is one of the earliest companies getting the CHO-K1 - CHO commercial license for commercial use and sublicense agreement from ECACC.

ProBio has two cell line development systems [https://www.probiocdmo.com/add-host-cell-license.html]: wild-type cell line CHOK1-GenS and ADCC-enhanced cell line CHOK1-ADCC +. CHOK1-GenS cell line development system without chemical . Developed ADCC enhanced host cell line (CHOK1-ADCC+), which can produce afucosylated monoclonal antibodies with enhanced ADCC activity. They are in together with the high-expression proprietary pGenHT 1.0-UP vector, the average titer of mAb is 5.7 g/L, the maximum titer of mAb is up to 15 g/L.

CHOK1 system exclusive advantages

IP Clear

- ECACC license agreement- Proprietary pGenHT 1.0-UP vector

Royalty Free

- One-time payment without royalty

2 CHO-K1 Host Cell License to Choose

- Wide type CHOK1-GenS- ADCC enhanced CHOK1-ADCC+

Combo license at discounted price

- Purchase in combination with wild type CHOK1-GenS cell line, and get a discounted price

Suitable for different type of proteins

- mAb/Protein

- BsAb,etc

Fulfill the regulatory requirements

- Fulfill the regulatory requirements of FDA,EMA and NMPA

Case Study of CHOK1-GenS cell line system [https://www.probiocdmo.com/add-host-cell-license.html]

High productivity with CHOK1-GenS system

* Suitable for different type of molecules

Image: https://www.probiocdmo.com/img/gsprobio/add-host-cell-license-image2-2024-07.png

Excellent stability with CHOK1-GenS system

* The titer at the end of stability study during fed-batch is recorded as T2.
* The titer at the beginning of stability study during fed-batch is recorded as T1.
* Titer variation=(T2-T1)/T1*100%
* Titer variation should be within 30%.

Image: https://lh3.googleusercontent.com/pw/AP1GczMB3f_9xxKlrjP6x87YRs4reMwErVO7Oq5sC5GFlMx8Oi8S7Nw_MVSrmhYOF9LPsRdWvOjtL3onlpNmKtHE20CC-HDnZgY-o5ft5_bcGn8k_c1SEpGx052Fcx3LkX3j7uwut1nGtE7F-N7cAOhlR7N7=w607-h663-s-no-gm?authuser=0

High productivity with CHOK1-GenS system

Titer prior to cell culture up to 15 g/L

Image: https://www.probiocdmo.com/img/gsprobio/add-host-cell-license-image3-1-2024.png

Excellent Stability in Scale-Up from 3L to 200L

Image: https://www.probiocdmo.com/img/gsprobio/add-host-cell-license-image4-1.png

Image: https://www.probiocdmo.com/img/gsprobio/add-host-cell-license-image5-1.png

Image: https://www.probiocdmo.com/img/gsprobio/add-host-cell-license-image7-1.jpg

Case Study of CHOK1-ADCC+ cell line system

CD16a 158V/F affinity (BLI)

Image: https://www.probiocdmo.com/img/gsprobio/add-procld-adcc-cell-line-development-services-case1.png

The affinity to CD16a (158V and 158F) was increased by 3-4 times.

PBMC-based ADCC

Image: https://www.probiocdmo.com/img/gsprobio/add-procld-adcc-cell-line-development-services-case2.png

* Cytotoxicity is increased by about 10%.
* Effect concentration (EC50) was reduced by 6 times.
* ADCC effect was significantly enhanced.

CHOK1 delivery package

Image: https://lh3.googleusercontent.com/pw/AP1GczPuJmMYMoyG2G0fMud0cddtKjkhExbOldAaZZj-NZwVDvRNQ-MdzAbwoZgYcHKPqqJ55mjCS4XLsbh59t5aMnonHJ1mo6TogN1CPB0jUUgxN1GVDCyStGO7ctt3T_1rNv-7VmNipQaL-eKdfUg43iSW=w985-h638-s-no-gm?authuser=0
Media Contact
Company Name: ProBio CDMO
Email: Send Email [http://www.universalpressrelease.com/?pr=probio-is-now-licensing-the-chok1-cell-line-development-system-to-biopharma-companies-for-commercial-use]
Phone: 1-877-436-7274 (Toll-Free)
Country: United States
Website: https://www.probiocdmo.com



This release was published on openPR.